Market Price

93.42 

-0.83 -0.9%

as of Aug 28 '15 10:23

52 Week Range:

41.99 112.40


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

Item Name Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14
Equity (BVPS) -6.11
-8.90
-15.15
1.85
-0.66
0.19
-0.25
0.12
1.31
2.19
2.27
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -100.0% 100.0% 991.7% 67.2% 3.7%
Earnings BIT -44.91
36.34
-174.27
-53.46
-97.52
-9.87
-15.40
-2.95
-3.87
9.21
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE -46.30
-17.00
-15.70
-20.90
-3.20
-34.50
-15.00
22.99
-118.50
121.95
98.34
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 100.0% -19.4%
ROA -14.25
-11.25
-9.91
112.83
-56.92
-1.24
-9.54
10.28
-0.47
10.93
6.63
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% -39.3%
ROE 36.10
36.70
-142.60
997.71
-1,046.50
-69.00
-365.80
536.00
-3.00
30.01
31.67
growth rate 1.7% -100.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% 5.5%
ROIC 561.34
-803.41
35.22
3.76
20.13
8.45
growth rate -100.0% 100.0% -89.3% 435.4% -58.0%
Cur. Ratio 0.80
0.57
1.38
2.16
1.33
1.31
1.11
0.74
0.67
0.86
8.13
growth rate -28.8% 142.1% 56.5% -38.4% -1.5% -15.3% -33.3% -9.5% 28.4% 845.4%
Quick Ratio 0.66
0.46
1.07
1.85
1.31
1.22
1.08
0.67
0.60
0.78
7.94
growth rate -30.3% 132.6% 72.9% -29.2% -6.9% -11.5% -38.0% -10.5% 30.0% 918.0%
Leverage 11.92
5.95
37.88
14.15
3.94
2.11
9.80
growth rate -50.1% 152.3% -38.9% -72.2% -46.5% 364.5%
Balance Sheet Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14
Acct.Receivable 0.00
0.60
1.00
12.54
8.92
6.55
12.96
growth rate 66.7% 1,154.4% -28.9% -26.5% 97.8%
Acct.Payable 16.12
12.40
10.86
12.82
growth rate -23.1% -12.4% 18.0%
Cur.Assets 93.90
68.20
37.00
32.23
23.82
24.88
185.16
growth rate -27.4% -45.8% -12.9% -26.1% 4.4% 644.2%
Total Assets 171.40
141.80
75.60
120.58
104.26
104.71
258.03
growth rate -17.3% -46.7% 59.5% -13.5% 0.4% 146.4%
Cash 28.80
16.00
3.30
7.04
12.38
11.64
160.20
growth rate -44.4% -79.4% 113.4% 75.8% -6.0% 1,276.4%
Inventory 0.00
0.00
0.00
1.30
1.70
1.39
0.27
growth rate 30.4% -18.0% -80.7%
Cur.Liabilities 70.60
52.20
33.50
43.64
35.44
28.94
22.78
growth rate -26.1% -35.8% 30.3% -18.8% -18.3% -21.3%
Liabilities 181.80
138.10
80.40
104.05
77.78
55.10
231.71
growth rate -24.0% -41.8% 29.4% -25.3% -29.2% 320.5%
LT Debt 171.09
170.18
2.16
0.63
49.70
36.30
0.00
28.65
19.41
3.07
196.84
growth rate -0.5% -98.7% -71.0% 7,826.6% -27.0% -100.0% -32.3% -84.2% 6,309.7%
Equity -98.07
39.70
41.46
1.98
3.70
3.50
8.19
26.49
49.61
26.32
growth rate 100.0% 4.4% -95.2% 86.9% -5.4% 133.9% 223.6% 87.3% -47.0%
Common Shares 12.00
12.00
13.00
16.00
16.00
19.00
20.00
20.00
20.00
21.00
21.00
growth rate 0.0% 8.3% 23.1% 0.0% 18.8% 5.3% 0.0% 0.0% 5.0% 0.0%
Cash Flow Statement Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14
Capital Expenditures 3.60
35.60
1.78
0.44
0.40
0.40
0.70
0.08
0.60
0.38
0.01
growth rate 888.9% -95.0% -75.3% -9.1% 0.0% 75.0% -88.9% 662.8% -36.6% -98.4%
Cash Dividends 0.00
0.00
0.00
252.74
0.00
0.00
0.00
0.00
0.00
growth rate -100.0%
Cash From OA 5.75
8.37
-138.52
-97.73
-20.63
-33.80
-27.07
-1.17
0.16
20.69
20.57
growth rate 45.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 12,750.9% -0.6%
FCF per Share 0.18
-0.86
-3.44
-6.00
-1.33
-1.82
-1.38
-0.42
-0.02
0.34
1.03
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 202.9%
Sale Purchase of Stock 0.00
6.42
3.13
-51.76
growth rate 100.0% -51.3% -100.0%
FCF 2.00
-27.00
-140.00
-98.00
-21.00
-34.00
-27.00
-1.00
-0.40
17.00
20.00
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 17.7%
Income Statement Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14
Sales 112.11
10.22
3.98
12.89
27.30
38.90
23.50
30.04
31.39
48.97
64.54
growth rate -90.9% -61.1% 223.9% 111.8% 42.5% -39.6% 27.8% 4.5% 56.0% 31.8%
Op.Income -97.30
-10.00
-29.30
9.71
-2.67
8.83
12.02
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% 36.1%
IBT -97.50
-9.90
-15.40
-3.56
-3.87
9.21
11.30
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 22.8%
Net Income -98.10
-1.90
-10.40
9.71
-2.67
8.83
12.02
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% 36.1%
EPS -3.66
-2.94
-2.34
17.22
-6.18
-0.12
-0.53
0.52
-0.03
0.55
0.56
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% 1.8%
Gross Profit 93.85
10.22
3.98
12.89
27.30
38.90
23.50
25.13
27.79
43.24
55.40
growth rate -89.1% -61.1% 223.9% 111.8% 42.5% -39.6% 6.9% 10.6% 55.6% 28.1%
R&D 30.80
39.90
22.10
10.29
10.79
9.27
12.12
growth rate 29.6% -44.6% -53.4% 4.9% -14.1% 30.7%

Quarterly Statements

Item Name Jun '14 Sep '14 Dec '14 Mar '15 Jun '15
Balance Sheet
Acct.Receivable 3.52
6.34
12.96
7.51
11.08
growth rate 79.8% 104.5% -42.0% 47.5%
Acct.Payable 9.87
10.75
12.82
11.96
8.34
growth rate 8.9% 19.3% -6.7% -30.3%
Cur.Assets 28.59
198.52
185.16
191.71
196.73
growth rate 594.5% -6.7% 3.5% 2.6%
Total Assets 99.85
272.28
258.03
263.22
304.76
growth rate 172.7% -5.2% 2.0% 15.8%
Cash 14.54
180.66
160.20
165.77
108.24
growth rate 1,142.8% -11.3% 3.5% -34.7%
Inventory 0.82
1.07
0.27
2.82
0.80
growth rate 31.1% -74.9% 948.7% -71.6%
Cur.Liabilities 18.62
18.43
22.78
18.16
17.95
growth rate -1.0% 23.6% -20.3% -1.2%
Liabilities 35.68
227.91
231.71
228.08
235.71
growth rate 538.8% 1.7% -1.6% 3.4%
LT Debt 1.59
193.63
196.84
198.80
200.80
growth rate 12,101.1% 1.7% 1.0% 1.0%
Equity 64.17
44.37
26.32
35.15
69.05
growth rate -30.9% -40.7% 33.6% 96.5%
Common Shares 20.78
growth rate
Cash Flow Statement Jun '14 Sep '14 Dec '14 Mar '15 Jun '15
Capital Expenditures -0.01
0.01
0.01
0.02
growth rate 100.0% 66.7% 70.0%
Cash Dividends
growth rate
Cash From OA 4.01
3.74
10.25
7.58
10.05
growth rate -6.8% 174.3% -26.0% 32.6%
Sale Purchase of Stock 0.45
-26.41
-28.99
0.78
4.65
growth rate -100.0% 0.0% 100.0% 495.3%
FCF 4.00
10.24
7.57
10.03
growth rate 60.0% -26.1% 32.5%
Income Statement Jun '14 Sep '14 Dec '14 Mar '15 Jun '15
Sales 10.61
14.97
23.00
14.60
18.42
growth rate 41.2% 53.6% -36.5% 26.1%
Op.Income 1.29
0.47
7.86
0.75
22.69
growth rate -63.3% 1,566.1% -90.4% 2,909.8%
IBT 1.24
0.90
7.01
-0.07
22.29
growth rate -27.3% 678.1% -100.0% 100.0%
Net Income 1.29
0.47
7.86
0.75
22.69
growth rate -63.3% 1,566.1% -90.4% 2,909.8%
EPS 0.07
growth rate
Gross Profit 9.42
13.48
19.00
13.53
15.82
growth rate 43.0% 41.0% -28.8% 16.9%
R&D 2.69
3.02
3.28
3.96
4.01
growth rate 12.3% 8.6% 20.8% 1.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (68.82)

YOY Growth Grade:

E (33.19)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 54.55 60.27 25.33
EPS / Growth 23.2% 1.55 44.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 28.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 23.2% 31.9% 31.9%
Future PE 25.33 47.91 47.91
Future EPS 12.49 24.74 24.74
Value Price
MOS %
78.18
-16.3%
292.99
213.6%
292.99
213.6%
MOS Price 39.09 146.50 146.50
IRT 12.04 9.90 9.90

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.